Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript

Haematologica

Volumn 94, Issue 10, 2009, Pages 1362-1367

  Lucas, Claire M ^a   Harris, Robert J ^a   Giannoudis, Athina ^a   Davies, Andrea ^a   Knight, Katy ^a   Watmough, Sarah J ^a   Wang, Lihui ^a   Clark, Richard E ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

BCR ABL fusion transcript; Chronic myeloid leukemia; Imatinib

Indexed keywords

BCR ABL PROTEIN; IMATINIB; MESSENGER RNA; ORGANIC CATION TRANSPORTER 1; PROTEIN TYROSINE KINASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; DRUG RESPONSE; ENZYME ACTIVITY; FEMALE; GENETIC TRANSCRIPTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHARMACOGENETICS; PROTEIN EXPRESSION; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; SURVIVAL RATE; TRANSCRIPTION, GENETIC;

EID: 70349635441     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.009134     Document Type: Article

References (25)

1. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343-3356 (Pubitemid 30836310)
2. Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. The chronic myelogenous leukemia-specific p210 protein is the product of the BCR/ABL hybrid gene. Science 1986;233:212-214 (Pubitemid 16008117)
3. Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J, et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 2007;109:4686-4692 (Pubitemid 46827759)
4. Lucas CM, Wang L, Austin GM, Knight K, Watmough SJ, Shwe KH, et al. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia 2008;22:1963-1966
5. de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-totreat analysis. J Clin Oncol 2008;26:3358-3363
6. Morris SW, Daniel L, Ahmed CM, Elias A, Lebowitz P. Relationship of bcr breakpoint to chronic phase duration, survival, and blast crisis lineage in chronic myelogenous leukemia patients presenting in early chronic phase. Blood 1990;75:2035-2041 (Pubitemid 20180294)
7. Polampalli SCN, Negi N, Shinde S, Baisane C, Amre P, Subramanian PG, et al. Analysis and comparison of clinicohematological parameters and molecular and cytogenetic response of two Bcr/Abl fusion transcripts. Gen Mol Res 2008;7:1138-1149
8. Rosas-Cabral A, Martínez-Mancilla M, Ayala-Sánchez M, Vela-Ojeda J, Bahena-Reséndiz P, Vadillo-Buenfil M, et al. Analysis of Bcr-abl type transcript and its relationship with platelet count in Mexican patients with chronic myeloid leukemia. Gaceta Méx 2003;139:553-559 (Pubitemid 38017460)
9. Meissner RDV, Dias PMB, Covas DT, Job F, Leite M, Nardi NB. A polymorphism in exon b2 of the major breakpoint cluster region (M-bcr) identified in chronic myeloid leukaemia patients. Br J Haematol 1998;103:224-226 (Pubitemid 28470823)
10. Perego RA, Costantini M, Cornacchini G, Gargantini L, Bianchi C, Pungolino E, et al. The possible influences of B2A2 and B3A2 BCR/ABL protein structure on thrombopoiesis in chronic myeloid leukaemia. Eur J Cancer 2000;36: 1395-1401 (Pubitemid 30421144)
11. Shepherd P, Suffolk R, Halsey J, Allan N. Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival. Br J Haematol 1995;89:546-554
12. Mills KI, Benn P, Birnie GD. Does the breakpoint within the major breakpoint cluster region (M-bcr) influence the duration of the chronic phase in chronic myeloid leukemia? An analytical comparison of current literature. Blood 1991;78:1155-1161
13. de Lemos JA, de Oliveira CM, Scerni AC, Bentes AQ, Beltrao AC, Bentes IR, et al. Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia. Gen Mol Res 2005;30:4:803-811
14. Vega-Ruiz A, Kantarjian H, Shan J, Wierda W, Burger J, Verstovsek S, et al. Better molecular response to imatinib for patients (pts) with chronic myeloid leukemia (CML) in chronic phase (CP) carrying the b3a2 transcript compared to b2a2. ASH Annual Meeting Abstracts 2007;110:1939.
15. Wang L, Pearson K, Pillitteri L, Ferguson JE, Clark RE. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. Br J Haematol 2002;118:771-777 (Pubitemid 35007381)
16. White D, Saunders V, Lyons AB, Branford S, Grigg A, To LB, et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 2005;106:2520-2526
17. Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2007;83:258-264
18. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-1820 (Pubitemid 44394987)
19. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004;104:3739-3745 (Pubitemid 39564452)
20. Meissner RDV, Covas DT, Dias PMB, Job F, Leite M, Nardi NB. Analysis of mRNA transcripts in chronic myeloid leukemia patients. Gen Mol Biol 1999;22:475-479 (Pubitemid 30047817)
21. Adler R, Viehmann S, Kuhlisch E, Martiniak Y, Röttgers S, Harbott J, et al. Correlation of BCR/ABL transcript variants with patients' characteristics in childhood chronic myeloid leukaemia. Eur J Haematol 2008;82:112-118
22. Prejzner W. Relationship of the BCR gene breakpoint and the type of BCR/ABL transcript to clinical course, prognostic indexes and survival in patients with chronic myeloid leukemia. Med Sci Mon 2002;8:193-197 (Pubitemid 34601809)
23. Jaubert J, Martiat P, Dowding C, Ifrah N, Goldman J. The position of the M-BCR breakpoint does not predict the duration of chronic phase or survival in chronic myeloid leukaemia. Br J Haematol 1990;74:30-35 (Pubitemid 20043569)
24. Tefferi A, Bren G, Wagner K, Schaid D, Ash R, Thibodeau S. The location of the Philadelphia chromosomal breakpoint site and prognosis in chronic granulocytic leukemia. Leukemia 1990;4:839-842
25. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in "goodrisk" chronic granulocytic leukemia. Blood 1984;63:789-799